China SXT Pharmaceuticals Operating Income

China SXT Pharmaceuticals (SXTC) currently reports a operating income of $-8.5M as of March 2026. That compares with $1.8M in the prior-year period — down 585.7% year over year. Use the charts on this page to explore China SXT Pharmaceuticals's operating income history and peer comparisons.

China SXT Pharmaceuticals's operating income decreased from $1.8M to $-8.5M — a 585.7% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

China SXT Pharmaceuticals reported $-8.5M in operating income as of March 2026. That compares with $1.8M in the prior-year period — down 585.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-8.5M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for China SXT Pharmaceuticals, and consider following SXTC for alerts when major investors trade the stock.

China SXT Pharmaceuticals is classified in the Consumer Discretionary sector. On operating income, it currently shows $-8.5M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Consumer Discretionary are usually more informative than comparing SXTC with unrelated industries.